Oxaliplatin 85 mg/m^2

DRUG2 trials

Sponsors

Hoffmann-La Roche, Al B. Benson, III, MD

Conditions

Colorectal CancerGastric CancerGastro-Esophageal Junction Adenocarcinoma

Phase 2

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

CompletedNCT03283761

Al B. Benson, III, MDGastric Cancer, Gastro-Esophageal Junction Adenocarcinoma

Start: 2017-09-21End: 2023-01-16Updated: 2024-02-06

Phase 3

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

CompletedNCT00069095

Hoffmann-La RocheColorectal Cancer

Start: 2003-07-31End: 2009-04-30Updated: 2016-10-06

Related Papers

Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2018-02-015 citations